Two phase 3 trials of Valneva's Pfizer-partnered Lyme disease vaccine candidate are nearing completion. (24K-Production/iStock/Getty Images Plus) Valneva has reported ...

The sale price fell within the $96.8 million to $118.3 million range Valneva had been hoping for. (InspirationGP/iStock/Getty Images Plus) Vaccine maker Valneva is ...

March 20 (Reuters) - French biotech company Valneva VLS.PA on Wednesday raised its product sales guidance and said it now expects revenues of between 170 million euros and 190 million euros ($184.72 ...

Add Yahoo as a preferred source to see more of our stories on Google. Illustration shows Valneva logo (Reuters) -France's Valneva on Wednesday said it expects to nearly double its annual product sales ...

Pfizer and Valneva entered into a collaboration agreement in April 2020 to co-develop VLA15, with updates to the terms in June 2022. Lyme disease is a bacterial infection that can be spread to humans ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Valneva SE (NASDAQ:VALN), on Monday, sold the FDA Priority Review Voucher (PRV) for $103 million (€95 million). The company was awarded a tropical disease PRV in November 2023 following the FDA ...

French biotech Valneva raises €84M via equity-linked placement and announces restructuring, with funds directed to late-stage Lyme vaccine VLA15 as stock hits 52-week low. Valneva Raises €84 Million ...

The U.S. health officials have recommended a pause in the use of French biotech Valneva’s (NASDAQ:VALN) chikungunya vaccine Ixchiq for those aged 60 years and older amid an ongoing safety review over ...

The U.S. Food and Drug Administration (FDA) late Friday announced that it has suspended the marketing application granted for French biotech Valneva’s (NASDAQ:VALN) chikungunya vaccine Ixchiq due to ...